Veeva Systems Inc. (VEEV) Q1 2027 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a positive outlook with strong financial performance and product development updates. Crossix's growth in digital channels and Falcon's potential as a new product are promising. Despite unchanged macro trends, Veeva's strategic acquisitions and CRM migration successes are positive indicators. The Q&A section revealed no major concerns, with management providing satisfactory answers. Overall, the sentiment is positive, suggesting a likely stock price increase.
Key Financial Performance
Total Revenue $883 million, ahead of guidance. No specific year-over-year percentage change or reasons for change mentioned.
Non-GAAP Operating Income $395 million. No specific year-over-year percentage change or reasons for change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue: Total revenue in the quarter was $883 million.
Non-GAAP Operating Income: Non-GAAP operating income was $395 million.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements and uncertainties: The company acknowledges that forward-looking statements regarding trends, strategies, and anticipated performance are subject to various risks and uncertainties, which could lead to material differences in actual results.
Guidance and performance updates: The company will not provide further guidance or updates on performance during the quarter unless done in a public forum, which could limit investor visibility and create uncertainty.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Total revenue: Total revenue in the quarter was $883 million with non-GAAP operating income of $395 million.
Execution: Our execution continues strong across the business.
Vision for industry AI: It's an exciting time for Veeva and for life sciences overall, as we execute against a clear vision for industry AI.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you expand on what Veeva Falcon is targeting and how it envisions customers operating in drug development with the interplay between Vault, Vault standard agents, and Falcon?
A:Veeva Falcon represents a new chapter for Veeva, focusing on software, AI, data, and consulting. Falcon operates at the agent layer, replacing jobs previously done by people using Veeva applications. These agents will perform tasks autonomously, requiring applications to operate in a headless manner. Falcon is disruptive because it leverages new AI technology to perform standardized tasks in life sciences, which was not possible before.
Q:What areas do you think pharma companies will lean into first with AI applications, and how should we think about the transition from traditional SaaS applications to AI in pharma?
A:Pharma companies are not transitioning from SaaS to AI applications but are adopting a new technical architecture called MAAP (Models, Agents, and Applications). They aim to become agentic biopharma, where agents handle repetitive tasks, allowing humans to focus on higher-value work. Examples include processing clinical trial documents and categorizing adverse events. Veeva is focusing on creating industry-specific agents to handle these tasks efficiently.
Q:Why did the R&D business only raise the full-year guidance by $5 million despite a strong start to Q1?
A:The R&D business is growing healthily, particularly in DevCloud and Quality Cloud. However, many products like eCOA, RTSM, EDC, Safety, and LIMS are still early in their lifecycle. While these products are scaling, their early stage of growth is driving the full-year guidance.
Q:What did you see in Crossix activity in terms of demand, deal size, and verticals, and how should we think about growth durability through the year?
A:Crossix had a strong quarter, benefiting from increased pharma spending in digital channels. Innovations like measuring new channels (e.g., OpenEvidence, Meta) are driving market share gains. The digital market is healthy, and Crossix is expected to remain a durable growth business.
Q:How does Veeva plan to address customization and flexibility in Falcon agents for industry-specific problems?
A:Falcon is designed to build and operate standard agents to solve industry-specific problems, not as a platform for customers to develop custom agents. For custom agents inside Veeva applications, customers can use Vault AI. Falcon focuses on simplifying and standardizing the industry by providing agents that perform specific tasks autonomously.
Q:How is Veeva pricing Falcon, and how are they deciding which labor roles to address with Falcon agents?
A:Falcon will likely be priced by the document or case, depending on the task. Veeva is targeting high-volume, repetitive tasks that are often outsourced, such as processing clinical trial documents and safety cases. These tasks are simpler and have a higher volume, making them ideal for automation.
Q:Will Falcon cannibalize any existing revenue streams, or will it be accretive?
A:Falcon will be accretive as it addresses a market Veeva does not currently serve. It complements existing systems of record and does not cannibalize them.
Q:Did macro trends improve in Q1 compared to when guidance was given, and what areas are showing strength or recovery?
A:The macro environment remained unchanged from when guidance was given. The business is performing well across commercial, DevCloud, and Quality Cloud. Customers are adept at navigating changes, and the end market remains strong and healthy.
Q:What is the update on top 20 CRM migration decisions, and when will Veeva focus on cross-sell opportunities?
A:Veeva has won 10 of the top 20 CRM migration decisions, with 4 decisions remaining. They expect to win the majority of these. Veeva is currently focused on migrations and will lean into cross-sell opportunities after these decisions are finalized.
Q:What drove the strength in professional services revenue, and is it a leading indicator of future subscription revenue?
A:The strength in professional services revenue was driven by strong project execution in R&D and business consulting, as well as Vault CRM migrations. However, services revenue is not a reliable leading indicator of subscription revenue, as it includes non-implementation-related work.
Q:What is the strategic rationale behind the Ostro acquisition, and how does it fit into Veeva's broader strategy?
A:Ostro is a brand engagement platform for biopharma companies to provide compliant, instantaneous answers to healthcare professionals and patients. It complements Veeva's Commercial Cloud by enabling better engagement and unlocking commercial evidence. Ostro is expected to contribute $10 million in revenue for the remaining three quarters of the year.
Q:What is the pipeline outlook for Development Cloud, and were there any top 20 wins in Q1?
A:The pipeline for Development Cloud is strong, with engagement across all customer segments. While there were no large top 20 wins in Q1, this was due to timing. Veeva is expanding Development Cloud's potential with initiatives like eSource, Falcon, and Vault AI, generating significant customer excitement.
Q:What is the progress on Falcon's development, and how closely is Veeva partnering with customers ahead of the early adopter launch?
A:Veeva is building the Falcon platform, assembling the team, and signing early agreements with customers to train agents using their data. The focus is on getting early customers live and happy. The development process is similar to other new products, with some efficiency gains from tools like Claude Code.
Q:How is Veeva addressing customer concentration risk within Crossix?
A:Crossix is diversified across measurements and audiences, with a broad customer base. While certain areas like GLP-1s may have higher spending, the overall business is not significantly impacted by individual customer pullbacks.
Q:Why would Veeva Basics customers be among the first to adopt Falcon?
A:Veeva Basics customers are smaller, nimble companies using standardized configurations and processes provided by Veeva. This makes it easier to implement Falcon agents without customization, allowing for smoother adoption.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether macro trends improved in Q1 compared to when guidance was given, stating only that the environment remained unchanged. Additionally, they did not provide specific details on the timeline for leaning into cross-sell opportunities after CRM migrations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conference Instructions
Director Investor
EVP Chief
Form Forward
Forward statement
Gunnar afternoon
Instructions conference
Relations Gunnar
Results Conference
Senior Director
Systems Results
afternoon Conference
aid understanding
conference Senior
expectation risk
fact today
factor filing
filing Form
forum aid
information obligation
investor presentation
measure today
reconciliation measure
release
statement today
understanding result
VEEV Transcript
Veeva Systems Inc. (VEEV) Q1 2027 Earnings Call Transcript
Positive6-3
The earnings call summary indicates a positive outlook with strong financial performance and product development updates. Crossix's growth in digital channels and Falcon's potential as a new product are promising. Despite unchanged macro trends, Veeva's strategic acquisitions and CRM migration successes are positive indicators. The Q&A section revealed no major concerns, with management providing satisfactory answers. Overall, the sentiment is positive, suggesting a likely stock price increase.
Veeva Systems Inc. (VEEV) Q4 2026 Earnings Call Transcript
Positive3-4
The earnings call indicates a strong financial performance with a 15% YoY revenue increase and improved operating margins, suggesting operational efficiency. The free cash flow growth of 20% further supports a positive outlook. However, the absence of dividend or buyback programs slightly tempers the sentiment. No concerning details emerged from the Q&A session. Overall, the positive financial metrics and operational improvements suggest a positive stock price movement in the short term.
Veeva Systems Inc. (VEEV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Veeva Systems Inc. (VEEV) Presents at Raymond James TMT & Consumer Conference Transcript
Neutral12-8
VEEV Slides
Veeva Systems Q4’26 slides: revenue beats forecast, margins strong2026-03-04
Veeva Systems Q3 2026 slides: revenue jumps 16%, margins expand to 45%2025-11-20
Veeva Systems Q2 2026 slides: revenue up 17%, operating margins expand2025-08-27
Veeva Systems Q1 2026 slides: Revenue jumps 17% as operating margins hit 46%2025-05-28
VEEV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
